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Abstract
Background:  For patients suffering of recurrent breast cancer within the irradiated breast,
generally mastectomy is recommended. The normal tissue tolerance does not permit a second full-
dose course of radiotherapy to the entire breast after a second breast-conserving surgery (BCS).
A novel option is to treat these patients with partial breast irradiation (PBI). This approach is based
on the hypothesis that re-irradiation of a limited volume will be effective and result in an acceptable
frequency of side effects. The following report presents a single center experience with
intraoperative radiotherapy (IORT) during excision of recurrent breast cancer in the previously
irradiated breast.
Methods: Between 4/02 and 11/06, 15 patients were treated for in-breast recurrences at a median
of 10 years (3–25) after previous EBRT (10 recurrences in the initial tumor bed, 3 elsewhere in-
breast failures, 2 invasive recurrences after previous DCIS). Additional 2 patients were selected for
IORT with new primary breast cancer after previous partial breast EBRT for treatment of
Hodgkin's disease. IORT with a single dose of 14.7 – 20 Gy 50 kV X-rays at the applicator surface
was delivered with the Intrabeam™-device (Carl Zeiss, Oberkochen, Germany).
Results: After a median follow-up of 26 months (1–60), no local recurrence occurred. 14 out of
17 patients are alive and free of disease progression. Two patients are alive with distant metastases.
One patient died 26 months after BCS/IORT due to pulmonary metastases diagnosed 19 months
after BCS/IORT. Acute toxicity after IORT was mild with no Grade 3/4 toxicities and cosmetic
outcome showed excellent/good/fair results in 7/7/3 cases.
Conclusion: IORT for recurrent breast cancer using low energy X-rays is a valuable option for
patients with recurrent breast cancer after previous radiotherapy.
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Background
External-beam radiotherapy (EBRT) of the breast after
breast conserving surgery (BCS) reduces the local breast
tumour recurrence rate from 25 – 30% to less than 10% at
10 years [1-6]. However, it is still a problem to find the
optimal therapy modality for the remaining 10% of breast
cancer patients presenting with a tumour recurrence years
after BCS and EBRT. The normal tissue tolerance does not
allow, even after years, a second full-dose course of radio-
therapy to the entire breast after a second BCS. Especially
for patients with small, localized recurrences, in whom a
local excision would technically be possible, mastectomy
is generally preferred over BCS for fear of worse outcome
due to omission of radiotherapy. This is particularly
unsatisfying, because recurrent breast tumours, with
increasing advances in diagnostic modalities and regular
follow-up visits, are often diagnosed at a very small
tumour size. Furthermore, the most common and sur-
vival-limiting problem for these patients is usually not the
local situation within the breast, but the increased risk of
developing distant metastases [7]. Finally, more than 90%
of all IBTRs occur in the vicinity of the index tumour [8,9].
A novel option is to treat these patients after re-resection
of the recurrent tumor with partial breast irradiation
(PBI). This approach is based on the hypothesis that re-
irradiation to a limited volume will be effective and result
in an acceptable frequency of side effects. Intraoperative
radiotherapy is one option to deliver high doses to a
restricted area at risk i.e. the adjacent tissue to the tumour
cavity after tumour resection. IORT can be delivered with
dedicated linear accelerators in the operation room or
novel mobile devices using electrons or low-energy x-rays
[e.g. [10,11]].
The following report presents a single center experience
with intraoperative radiotherapy (IORT) to a partial breast
volume during excision of recurrent breast cancer in a pre-
viously irradiated breast. The technical and radiobiologi-
cal aspects of this treatment method using low-energy soft
X-rays were described in detail previously [12-15]. KV X-
rays are amongst others characterized by a sharp dose fall-
off to the tissue depth. If a dose of 20 Gy is prescribed to
the applicator's surface for example, the dose in 1.0 cm is,
depending on the applicator size, only 5 Gy, but due to
their different radiobiologic behaviour, a comparison
between the dose delivered by photons/electrons or soft
X-rays is not approvable.
Methods
Included in this analysis were all 17 patients with breast
cancer in a previously irradiated breast who presented
consecutively in the interdisciplinary tumourboard at the
Mannheim Medical Center/University of Heidelberg
between 4/2002 and 11/2006. The medical ethics com-
mittee II (University of Heidelberg) stated that ethics
approval is not needed for this retrospective analysis.
Median age was 65.8 years (48.3–86.9). All patients had
previous EBRT to the breast, 13 due to primary breast can-
cer, 2 due to DCIS and 2 due to EBRT of the mediastinal
and axillary lymph nodes because of Hodgkin's disease.
For previous treatment and exact total delivered dose, see
patient characteristics in Table 1. 10/17 patients had the
same histology and tumour localization (same quadrant)
as their primary breast cancer (true in-breast tumour
recurrences, IBTR, for a representative patient example see
figures 1, 2, 3), 3/17 presented with recurrences with a dif-
ferent histology, but the same localization and were cate-
gorized as secondary breast cancers. 2/17 had previous
EBRT due to DCIS and developed invasive recurrences
during further follow-up. Finally 2/17 patients developed
invasive breast cancer after treatment for Hodgkin's dis-
ease years before. Median duration between EBRT for pri-
mary and IORT for recurrent disease was 10 years (3–25)
and median recurrent tumour size was 11 mm (1–35
mm). At time of IORT, the exact status of the margins was
not known, but specimen-x-rays were done in any case
and could show the complete resected tumours. Defini-
tive pathology results showed afterwards a median margin
size of 3 mm with a range between 1 and 10 mm. IORT
was delivered with the Intrabeam™-device (Carl Zeiss,
Oberkochen, Germany). This system includes several
spherical applicators ranging from 1.5 to 5.0 cm in diam-
eter, resulting in an isotropic dose-distribution of 50 kV X-
rays with a very sharp dose-fall off. This device has been
used in our institution since 2/2002 in more than 220
breast cancer cases. The median applicator size used for
Breast-ultrasound for routine follow-up of a patient (no.17,  16 years after primary breast cancer) showed a small hypoe- chogeneity within the previous index quadrant Figure 1
Breast-ultrasound for routine follow-up of a patient (no.17, 
16 years after primary breast cancer) showed a small hypoe-
chogeneity within the previous index quadrant.BMC Cancer 2007, 7:178 http://www.biomedcentral.com/1471-2407/7/178
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Table 1: Patient characteristics part I
Pat.No. Age * Type of recurrence** Years after primary 
disease
Histology primary 
disease
Histology recurrent 
disease
Local therapy of 
primary disease
1 53.9 IBTR 3 lob-inv lob-inv BCS + 56 Gy
2 67.2 IBTR 3 duct-inv duct-inv BCS + 56 Gy
3 52.1 SBC. 4 duct-inv aden-cyst BCS + 62 Gy
4 65.8 SBC 9 lob-inv duct-inv BCS + 56 Gy
5 80.7 IBTR 11 lob-inv lob-inv BCS + 56 Gy
6 70.6 IBTR 4 duct-inv duct-inv BCS + 49 Gy
7 74.1 IBTR 9 lob-inv lob-inv BCS + 56 Gy
8 53.9 SBC 13 lob-inv duct-inv BCS + 56 Gy
9 48.3 IBTR 14 duct-inv duct-inv BCS + 50 Gy
10 75.8 IBTR 17 duct-inv duct-inv BCS + 56 Gy
11 78.0 IBIR 10 DCIS duct-inv BCS + 56 Gy
12 60.8 IBTR 14 muc-inv muc-inv BCS + 56 Gy
13 58.0 IBTR 7 duct-inv duct-inv BCS + 56 Gy
14 58.5 IR 10 DCIS duct-inv BCS + 56 Gy
15 86.9 IBTR 16 duct-inv duct-inv BCS + 56 Gy
16 56,8 BC after Hodgkin 5 nodular duct-inv Med 30 Gy
17 66.2 BC after Hodgkin 25 nodular duct-lob-inv Med 40 Gy
* Age at time of IBTR, ** Different types of recurrences:
IBTR = In-breast tumour recurrences (which have the same histology and localization)
SBC = Secondary breast cancer (which show a different histology)
IR = Invasive recurrences (after previous DCIS)
BC after Hodgkin = invasive breast cancer after Hodgkin's disease.
Histologies: Duct-inv = ductal-invasive, lob-inv = lobular-invasive, DCIS = Ductal carcinoma in situ, muc-inv = mucinous-invasive, 
nodular = nodular Hodgkin's disease, duct-lob-inv = mixed histology, partly ductal-invasive, partly lobular-invasive.
Local therapy of primary disease: BCS = breast conserving surgery
Med 30/40 Gy = the two patients with Hodgkin's disease were treated by involved field radiotherapy to the mediastinal lymph nodes 
with 30/40 Gy respectively.
Table 2: Patient characteristics part II:
Pat.No. Systemic therapy 
of primary disease
Systemic therapy 
of secondary 
disease
Recurrent tumour 
size (mm)
Applicator size 
IORT (cm)
Dose IORT (Gy) Treatment time 
IORT (Min)
1 GnRH Tamoxifen 12 3.5 20,0 18,60
2 6 × CMF AI 35 5.0 14,7 35,90
3 None GnRH 1 3.5 20,0 18,60
4 Tamoxifen AI 16 4.5 14,7 28,70
5 Tamoxifen AI 16 4.5 14,7 28,70
6 Tamoxifen AI 12 4.0 20,0 26,80
7 None AI 8 3.0 20,0 24,98
8 None Tamoxifen 7 4.0 20,0 26,80
9 6× CMF + Tam AI 15 4.0 20,0 26,80
10 3× CMF + Tam AI 18 4.0 20,0 26,80
11 None Tam 10 4.0 20,0 28,26
12 None AI 9 3.5 20,0 19,9
13 None none 11 5.0 20,0 49,5
14 None none 11 3.5 20,0 19,9
15 4× EC + Tam AI + GnRH 11 3.0 20,0 26,4
16 4× ABVD leftTamoxifen 11 2.5 20,0 19,2
17 none 4 × FEC 11 5.0 20 49.50
GnRH = Gonadotropin Releasing-Hormone Analoga, Tam = Tamoxifen, CMF = Cyclophosphamide (600 mg/m2)/Methotrexate (40 mg/m2)/5-
Fluorouracil (600 mg/m2)
EC = Epirubicin (90 mg/m2)/Cyclophosphamide (600 mg/m2), AI = Aromatase inhibitors
ABVD = Adriamycin, Bleomycin, Vinblastin, DTICBMC Cancer 2007, 7:178 http://www.biomedcentral.com/1471-2407/7/178
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these 17 patients was 4.0 cm (2.5–5.0), median dose at
the applicator surface was 20.0 Gy (14.7–20.0) and
median treament time was 26.8 minutes (18.6–35.9). In
addition, 3/17 patients were treated by chemotherapy and
14/17 by hormonal therapy. Exact type of systemic thera-
pies is shown in Table 2. All patients underwent a pro-
spective, predefined follow-up including clinical
examination and breast-ultrasound at 6 monthly and
mammographies at yearly intervals. Toxicities were docu-
mented using the CTC/EORTC- and the LENT SOMA-
score. Cosmesis was evaluated with a 1–4 score as previ-
ously published [15].
Results
After a median follow-up of 26 months (1–60), 16 out of
17 patients are still alive. One patient (no.3) with second-
ary breast cancer with an uncommon adenoid-cystic
breast tumour (primary breast cancer 4 years before has
been ductal-invasive) died 26 months after BCS/IORT due
to pulmonary metastases that were diagnosed 19 months
after treatment for recurrence. Two other patients had dis-
tant metastases (retroorbital and bone) before and after
treatment of their primary breast cancer. All localizations
were treated by palliative EBRT and systemic treatment
with bisphosphonates. Both patients are still alive in good
overall condition.
Acute toxicity after IORT was mild with no Grade 3/4 tox-
icities and there was no delay in wound healing nor any
wound infection. 6/17 patients (35.3%) showed a limited
induration of the tumourbed. In 3/17 (17.6%) cases the
induration of the area treated with IORT was judged as
moderate to severe.
The cosmetic outcome after a median follow-up of 26
months was satisfactory with excellent/good/fair results in
7/7/3 cases. All 3 patients with only fair cosmetic results
had already small breast volumes after previous BCS and
EBRT and developed a moderate/severe induration of the
remaining breast tissue after second intervention, which
resulted in a suboptimal cosmetic outcome.
Discussion
Mastectomy is the current standard of care for IBTR of
breast carcinoma, but there are some reasonable argu-
ments for a second breast-conserving approach:
1. The risk of local recurrence is not eliminated by using
mastectomy. Approximately 2–32% of patients treated
Oblique mammography of the same patient Figure 3
Oblique mammography of the same patient.
Craniocaudal mammography of the same patient with a small  dense structure suspicious for recurrent breast cancer Figure 2
Craniocaudal mammography of the same patient with a small 
dense structure suspicious for recurrent breast cancer. This 
non-palpable lesion was marked by a wire before surgery.BMC Cancer 2007, 7:178 http://www.biomedcentral.com/1471-2407/7/178
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with mastectomy for recurrent breast cancer develop a
chest wall recurrence [17].
2. In the NSABP-B06 protocol, IBTR was an independent
predictor of distant disease with an adjusted relative risk
of 3.41 [7]. A previously published analysis comparing
the data of 2669 patients from 5 NSABP node positive
protocols (B15, 16, 18, 22 and 25) confirmed these results
and found that 5 years after IBTR, only 51.4% of the
patients were free of distant disease [18]. The time prior to
IBTR has been proposed to be an additional prognostic
factor for survival. If IBTR occurred within 5 years of initial
therapy, the 5-year overall-survival rate and the 5-year dis-
tant-recurrence-free survival rate was 65% and 61%
respectively, compared to patients with IBTR 5 or more
years after initial diagnosis showing an overall-survival
rate of 81% and a 5-year distant-recurrence-free survival
rate of 80% [19]. Consequently, the spread of distant
tumour cells seems to be the survival-limiting problem of
patients with IBTR, not the risk of re-recurrences within
the breast. Recurrences elsewhere in the ipsilateral breast
or second primaries may have a completely different
behaviour, because theoretically these tumours represent
de novo disease rather than persistent, radioresistant,
drug-insensitive disease [18].
There are a few reports about acceptable long-term control
rates after BCS with or without additional radiotherapy:
52/118 patients with IBTR after BCS and EBRT for stage I
or II breast cancer were selected for salvage treatment with
wide excision, with or without axillary dissection, instead
of mastectomy [20]. With a median follow-up of 6 years,
the actuarial cancer-specific survival after treatment of
recurrence was 79% at 5 years and 64% at 10 years. The
local control rate in the treated breast was 79% at 5 years.
Of 12 patients in whom second local or regional recur-
rences developed, ten could be treated by further surgery.
The authors concluded that wide excision represents an
adequate alternative to mastectomy in the salvage treat-
ment of isolated breast recurrences at least for selected
patients (mobile tumours, 2 cm or smaller in diameter, no
signs of rapid growth) [20]. The same investigator group
reported the feasibility of conservative salvage surgery in a
clinicopathologic study 3 years later. After wide excision
for 50 selected patients with IBTR after standard BCS, 16
(32%) second local failures occurred after a median fol-
low-up of 51 months (5-year local control 62%). A Cox
multivariate analysis of 18 parameters indicated that only
disease-free interval and resection margins significantly
influenced local control. 5-year local control was 92% for
recurrences occurring after 5 years vs. 49% for shorter
intervals, and 73% for negative vs. 36% for positive or
indeterminate margins. Local control appeared to be inde-
pendent of morphologic features, initial tumour stage,
patient age, recurrent tumour size and location. Median
survival after second local failure was 33 months. Particu-
larly for late recurrences, wide excision with negative mar-
gins seems to be a satisfactory alternative to mastectomy
[21]. Another report on 16 patients with IBTR after BCS
and EBRT (median interval between first BCS and IBTR 31
months) exists, who refused mastectomy and were treated
with repeat lumpectomy and radiotherapy. 15 patients
were treated with a total dose of 50 Gy and a fractional
dose of 2 Gy and 1 patient with a total dose of 32 Gy and
a fractional dose of 2 Gy to the tumourbed. After a follow-
up between 42 and 119 months, 4 patients had further
local failure (2 of them additionally distant metastases),
10 patients are alive and free of disease and 2 patients
developed distant metastases. The authors concluded that
a repeat course of radiotherapy for an IBTR for selected
patients is well tolerated without any severe late sequelae
and may provide long-term local control [22]. The same
group again evaluated the outcome of another 23 patients
with an IBTR (median interval between first BCS and IBTR
63 months) after lumpectomy and breast irradiation for
invasive carcinoma (n = 31) or ductal carcinoma in situ (n
= 8), who were treated with excision of the IBTR and EBRT
of the tumour bed with 50 Gy in 25 fractions using elec-
trons of appropriate energy. Again, the second course of
EBRT was well tolerated in all patients with no other late
sequelae than skin pigmentation changes. 30 patients
(76.9%) had an intact breast free of tumor at death or at
last follow-up 1–180 months (median 51.5) after reirradi-
ation and 8 patients developed distant metastases. The
estimated overall and disease-free 5-year survival rate for
the 39 patients was 77.9% and 68.5%, respectively. The
conclusion was drawn that the excision of the IBTR fol-
lowed by repeat external beam RT to the operative area
may be an acceptable alternative to mastectomy for
selected patients [23]. Early follow-up studies of breast
reirradiation suggest also that beside standard external
beam radiation therapy, catheter-based interstitial brach-
ytherapy can be delivered to the breast more than once
without inacceptable side effects in most patients. with
acceptable cosmesis in some patients. Mastectomy may
not be necessary in all patients with an in-breast local
recurrence of breast carcinoma [17]. 69 patients with IBTR
after previous lumpectomy and radiotherapy were treated
in France by second breast conserving surgery and intersti-
tial brachytherapy with a total dose of either 30 (n = 24)
or 45–50 Gy (n = 45). Catheters were implanted in all
cases immediately after tumour resection and radiother-
apy started 5 days after surgery. Five-year disease free sur-
vival after first local recurrence was 77%. After a median
follow-up of 50 months, up to 22% grade 2 and 3 long
term side-effects like fibrosis, breast retraction or
teleangiectasia occurred [24].BMC Cancer 2007, 7:178 http://www.biomedcentral.com/1471-2407/7/178
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Comparing the results of the above mentioned studies to
our data, regarding toxicity of the reirradiated patients,
several parallels could be identified, particularly with the
latter brachytherapy study. One advantage of the reirradi-
ation with IORT compared to interstitial brachytherapy,
where patients have to be irradiated over several days, is
certainly the time-saving single day treatment.
The role of additional systemic therapy in the manage-
ment of IBTR remains uncertain. Although the use of hor-
monal therapy has been shown to be effective [25,26], the
benefit of chemotherapy has not been adequately evalu-
ated in prospective randomized trials [18].
A limited number of reports about the use of radiotherapy
for breast cancer after irradiation of Hodgkin's disease has
been published. The group from Milan [27,28] reported a
lack of acute complications and good cosmetic results in
6 patients undergoing IORT during BCS years after Mantle
field irradiation. Deutsch et al [29] described 12 patients
treated with full-dose EBRT after BCS for breast cancer in
previously irradiated breasts following radiotherapy for
Hodgkin's disease.
Conclusion
This is to our knowledge the first report about IORT using
50 kV X-rays for recurrent breast cancer in a previously
irradiated breast tissue. No unexpected toxicities were
observed during a median follow-up of more than 2 years.
IORT of the tumourbed may become an alternative to
mastectomy for selected patients with an IBTR after previ-
ous breast irradiation.
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